Trials / Completed
CompletedNCT05847413
Targeting Beta Cell Dysfunction With Verapamil in Longstanding T1D
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Benaroya Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether verapamil can transiently improve beta cell function in those who do or do not secrete proinsulin and little/no C-peptide.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Verapamil | Subjects will receive oral verapamil for 12 weeks |
Timeline
- Start date
- 2020-05-30
- Primary completion
- 2021-12-10
- Completion
- 2021-12-10
- First posted
- 2023-05-06
- Last updated
- 2023-05-06
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05847413. Inclusion in this directory is not an endorsement.